The therapeutic utility of cytochrome P450-based enzyme prodrug therapy is well established by preclinical studies and in initial clinical trials. The underlying premise of this gene therapy is that intratumoral P450 expression leads to in situ activation of anticancer P450 prodrugs, such as cyclophosphamide (CPA), with intratumoral accumulation of its activated 4-OH metabolite. In mice bearing 9L gliosarcomas expressing the CPA 4-hydroxylase P450 2B6, enhanced tumor apoptosis was observed 48 h after CPA treatment; however, intratumoral 4-OH-CPA levels were indistinguishable from those of P450-deficient tumors, indicating that the bulk of activated CPA is derived from hepatic metabolism. In contrast, in 9L tumors expressing P450 2B11, a low K m CPA 4-hydroxylase, intratumoral 4-OH-CPA levels were higher than in blood, liver and P450-deficient tumors. Intratumoral 4-OH-CPA increased dose-dependently, without saturation at 140 mg kg À1 CPA, suggesting restricted tumor cell permeation of the parent drug.
Introduction
The chemosensitization of tumor cells by intratumoral (i.t.) activation of anticancer prodrugs is an emerging adjuvant therapy that can increase the efficacy of several commonly used anticancer agents. Intratumoral prodrug activation may be enhanced by introduction of prodrugactivation enzymes of bacterial, viral or mammalian origin using a variety of gene therapy vectors, including retroviruses, adenoviruses, herpes viruses, as well as nonviral vectors. [1] [2] [3] Chemosensitization is achieved when an anticancer prodrug is activated locally in tumor cells, which augments cytotoxic responses, both in the prodrugactivating tumor cell and in naive bystander tumor cells exposed to diffusible cytotoxic metabolites.
One such prodrug activation therapy utilizes genes that encode mammalian cytochrome P450 enzymes. 4, 5 Drug metabolizing P450 enzymes are highly expressed in the liver and are generally found at very low levels in human tumors. 6, 7 These enzymes catalyze the metabolism of more than 35 anticancer drugs, 8, 9 of which 12 drugs, including the widely used alkylating agent prodrug cyclophosphamide (CPA) and its isomer ifosfamide (IFA), are activated via P450 metabolism. 10 CPA is used in both adjuvant and highdose chemotherapy settings and is effective against a broad range of tumors, including breast cancer and lymphomas. 11 Two hepatic cytochromes P450, P450 2B6 and P450 3A4, catalyze a substantial fraction of CPA activation in human liver with electron input from NADPH P450 reductase. 12 CPA is converted to 4-OH-CPA, a cell cycle-independent alkylating metabolite that readily diffuses out of hepatocytes and can exert cytotoxicity at distant sites, including tumor and sensitive host tissues. This intrinsic diffusibility of 4-OH-CPA underlies the bystander cytotoxic response that is obtained when CPA is combined with P450-prodrug gene therapy. 13 The efficacy of P450 gene therapy can be enhanced in several ways, including combination with bioreductive prodrugs that are activated by P450 and/or P450 reductase, 14, 15 by using a metronomic, antiangiogenic CPA treatment schedule, 16, 17 and by using tumor cellreplicating herpes virus 18 and adenovirus 19 to spread the therapeutic P450 gene and augment tumor cell lysis.
In the present study we investigated the activation of CPA in vivo in solid tumors that express P450 in an effort to improve the pharmacokinetics of CPA metabolism and enhance the efficacy of this P450 prodrug-activation strategy. Our findings demonstrate that despite an increase in chemosensitivity, tumor cell expression of the high K m CPA 4-hydroxylase enzymes P450 2B6 and P450 2B1, used in recent clinical trials, 20, 21 does not lead to a measurable increase in i.t. 4-OH-CPA levels. In contrast, introduction of P450 2B11, a low K m CPA 4-hydroxylase, 22 increases the i.t. concentration of 4-OH-CPA above that found in P450-deficient tumors. Further improvements in i.t. pharmacokinetics and increased net tumor cell exposure to 4-OH-CPA were obtained by direct i.t. CPA delivery via a slow-release polymer, substantially enhancing the overall antitumor response.
Materials and methods

Materials
CPA, chloroquine and puromycin were purchased from Sigma-Aldrich (St Louis, MO). 4-hydroperoxy-CPA was obtained from ASTA Pharma (Bielefield, Germany). IFA was obtained from the Drug Synthesis and Chemistry Branch of the National Cancer Institute (Bethesda, MD). Fetal bovine serum (FBS) and Delbecco's modified Eagle's medium (DMEM) were purchased from Life Technologies (Grand Island, NY). F127, a 12 600 average molecular weight ethylene oxide and propylene oxide block copolymer 23 (also known as Pluronic F127, poloxamer 407 and Pluracare F-127 Prill Surfactant), was obtained from BASF Corporation (Florham Park, NJ) and contained 100 p.p.m. BHT. Rat 9L gliosarcoma cells were grown in a humidified, 5% CO 2 atmosphere at 37 1C in DMEM containing 10% FBS, 100 units ml À1 penicillin and 100 mg ml À1 streptomycin. Casputin (catalog no. SE760) and the caspase 3 substrate Ac-DEVD-AMC (catalog no. P-411) were purchased from Biomol International LP (Plymouth Meeting, PA).
9L tumors expressing P450 and pharmacokinetic studies 9L gliosarcoma cells were infected with pBabe-based retrovirus expressing P450 2B1, P450 2B6 or P450 2B11 cDNA linked to P450 reductase cDNA via an internal ribosome entry site sequence (9L/2B1, 9L/2B6 and 9L/2B11 cells, respectively) as described. 24 9L cells infected with an empty pBabe-based retrovirus were used as P450-deficient controls. Immunochemical analysis using anti-P450 2B antibodies revealed P450 2B expression in B90-95% of the cultured 9L/2B cells. This percentage decreased to B50% or less of the cells when grown subcutaneously as solid tumors (J Ma and DJ Waxman, unpublished observations). 9L tumor cells were grown to near-confluence in DMEM culture medium containing 10% FBS, harvested by trypsin digestion, washed once, and resuspended in FBS-free DMEM and placed on ice. Five-week-old (23-25 g) male ICR/Fox Chase outbred immunodeficient scid mice (Taconic Farms, Germantown, NY) were injected subcutaneously on each flank with 4 Â 10 6 9L, 9L/2B1, 9L/2B6 or 9L/2B11 cells in 0.2 ml of FBS-free DMEM using an 0.3 ml U-100 insulin syringe and a 28G-1/2 needle. All mice were housed and treated in the Boston University Laboratory of Animal Care Facility using approved animal protocols.
Pharmacokinetic data were collected when the tumors reached 800-1000 mm 3 in size. Mice were given a single injection of CPA or IFA at doses specified in each experiment, either by intraperitoneal (i.p.) injection or by direct i.t. injection as described below. In some cases, CPA was dissolved in 0.2% NaCl or in a 23% solution of F127 dissolved in 0.2% NaCl and then injected i.t. as specified in each experiment. The final CPA concentration was adjusted to 12.5-14 mg ml À1 based on each individual mouse's body weight (BW) to keep the injected volume (60 ml per tumor) and the CPA dose (50 mg kg À1 BW) constant. Intratumoral CPA delivery was achieved using a syringe pump (model KDS100; KD Scientific, Holliston, MA) set a 1 ml s À1 with a 30-gauge needle (20 ml per injection Â 3 injection sites per tumor). A 23% F127 polymer solution was prepared as follows: 3 g of F127 was dissolved in 7.0 ml of sterile 0.2% NaCl with shaking at 4 1C over a 24-h period to obtain a 30% F127 solution. A sterile solution of 60 mg ml À1 CPA was sonicated before use and then mixed with the required volume of 30% F127 stock solution to achieve a final concentration of 23% F127. Thus, for a 30 g mouse to be treated with 1.5 mg CPA (i.e., 50 mg CPA kg À1 BW), 208 ml of 60 mg ml À1 of CPA solution was mixed with 767 ml of 30% F127 and 25 ml of 0.2% NaCl. A volume of 60 ml was then injected directly into each tumor. Mice were killed 6, 15, 30, 60, 120 and 240 min after CPA treatment (n ¼ 3 mice per time point).
4-OH-CPA levels were assayed in 200-400 ml of blood collected by heart puncture using a syringe containing 10 ml of heparin at 100 U ml À1 and 2-4 ml of 0.5 M semicarbazide (final concentration 5 mM) to stabilize the 4-OH-CPA. The concentration of 4-OH-CPA in liver and in tumor was determined using B0.4 g of tissue prewashed with 0.1 M KPi buffer, pH 7.4 containing 0.1 mM EDTA and 5 mM semicarbazide. Tissues were homogenized using a Polytron homogenizer, model PT-2000 (Kinematica, Luzern, Switzerland), in 0.1 M KPi buffer containing 0.1 mM EDTA and 5 mM semicarbazide (5 ml per gram tissue). Homogenized blood, liver and tumor samples were centrifuged in Sorvall SA-600 rotor at 3000 r.p.m. for 30 min at 4 1C, and supernatants were stored at À80 1C prior to high-performance liquid chromatography analysis.
Tumor caspase activity assay Extracts were prepared from 9L and 9L/2B6 tumors (8807100 mm 3 ) 24 or 48 h after CPA treatment and then assayed for caspase 3 activity using the fluorogenic caspase 3 substrate Ac-DEVD-AMC as described. 25 Briefly, 0.5 g of tumor tissue was homogenized in 2 ml of lysis buffer (10 mM HEPES, pH 7.4, containing 2 mM EDTA, 0.1% CHAPS, 5 mM DTT, 2 mM PMSF, 10 mg ml À1 pepstatin, 10 mg ml À1 aprotinin and 20 mg ml rotor. 26 The resulting supernatant (20 mg protein at 1 mg ml À1 ) was incubated for 1 h at 37 1C with 500 ml of 50 mM Ac-DEVD-AMC in 10 mM HEPES, pH 7.4, containing 2 mM EDTA, 0.1% CHAPS and 5 mM DTT. The caspase 3 component of this activity was determined in a parallel set of assays carried out after the supernatant fraction was preincubated for 15 min at room temperature with 5 ml of the caspase 3 inhibitor Casputin. Fluorescence was measured (excitation 380 nm, emission 460 nm) using a Shimadzu model RF-1501 spectrofluorophotometer.
Quantification of 4-OH-CPA 4-OH-CPA levels in blood, liver and tumor were determined as described previously. 22 Liver and tumor homogenates were prepared as described above. Blood samples (50 ml) were diluted to 500 ml with 0.1 M KPi buffer, pH 7.4, containing 0.1 mM EDTA and 5 mM semicarbazide. Blood and tissue samples (500 ml) were deproteinized by the sequential addition of 250 ml of 5.5% zinc sulfate and 250 ml of saturated barium hydroxide. Acrolein formed during from the chemical decomposition of 4-OH-CPA was derivatized to 7-hydroxyquinoline and analyzed by high-performance liquid chromatography. A standard curve was generated from 4-hydroperoxy-CPA (0-40 mM) dissolved in KPi buffer and processed in parallel (limit of detection (twice background), 0.3 nmol g À1 tissue). Integrated peak areas determined by Millennium 32 software (Waters Corpn, Milford, MA) were then converted into units of nanomole 4-OH-CPA produced per gram tissue.
Pharmacokinetics data analysis A simple noncompartmental model was used to calculate values for area under the curve (AUCINF observed ), t 1/2 , maximum concentration (C max ) and T max for 4-OH-CPA in blood, liver and tumor using WinNonLin software version 1.5 (Scientific Consulting Inc., Apex, NC). 4-OH-CPA levels in tissue samples derived from CPA-treated mice were corrected for background activity (that is, endogenous acrolein levels) based on the activity measured in the corresponding tissue samples obtained from untreated mice. To calculate pharmacokinetic parameters, the time course data for each tissue was randomly assigned into three separate datasets, each comprised of a full set of data points obtained for one of the three mice killed at each time point. The Descriptive Statistics module of WinNonLin software was used to calculate values for AUCINF observed , t 1/2 , C max and T max on the final parameters table in the form of mean values7s.e.m. Statistical comparisons using a nonparametric t-test were performed using Prism software version 4 (GraphPad Software, San Diego, CA).
Tumor growth delay studies 9L/2B11 cells were grown and implanted subcutaneously in ICR/Fox male scid mice as described above. Tumors were grown to a size of B500 mm 3 , at which time the mice were given two CPA injections at 150 mg kg À1 BW spaced 24 h apart. Mice were divided into three groups (n ¼ 5 mice and n ¼ 10 tumors per group). One group of mice was administered with CPA i.p. (25 mg ml À1 CPA stock in 0.2% NaCl; systemic delivery). The other groups of mice were injected with CPA, i.t., in a 23% solution of F127 prepared in 0.2% NaCl, using a syringe pump with 30-gauge needle at 1 ml s À1 as described above. Cyclophosphamide was dissolved in the 23% F127/0.2% NaCl vehicle at concentrations ranging from 18.7 to 21.4 mg CPA ml À1 based on the weight of each mouse to insure an equal dose of CPA and an equal dose of F127 polymer per mouse. Thus, for a 30 g mouse, a dose of 150 mg CPA kg À1 BW (i.e., 4.5 mg CPA 30 À1 g mouse) was achieved by dissolving 20 mg of CPA Á H 2 O in 1 ml of 23% F127/0.2% NaCl solution, whereas for a 32 g mouse, 21.4 mg of CPA Á H 2 O was dissolved in 1 ml of 23% F127/ 0.2% NaCl solution. In both cases, a total of 240 ml of the CPA/F127/NaCl solution was injected i.t. (6 Â 20 ml injected into each tumor). Control mice were injected with 240 ml of 0.2% NaCl. Tumor sizes (length L and width W) were measured twice a week using an electronic digital caliper (VWR international, Marlboro, MA). A second CPA treatment cycle was administered when the tumors reached a size of B800 mm 3 , that is, day 35 after the first CPA treatment. Tumor volumes were calculated using the formula:
3/2 . Percent tumor regression was calculated as 100 Â (V 1 -V 2 )/V 1 , where V 1 is the tumor volume on the day of drug treatment and V 2 is the volume corresponding to the maximum observed decrease in tumor size following drug treatment. Tumor doubling time was calculated as the period of time required for tumors to double in volume after the second drug treatment. 27 Results CPA-induced apoptosis in 9L/2B6 tumors Scid mice bearing 9L/2B6 or P450-deficient 9L control tumors were treated with CPA and killed 24 or 48 h later. Tumor homogenates were prepared and assayed for the activity of caspase 3, an effector caspase that is activated in CPA-treated 9L tumor cells. 25 CPA induced a significantly greater increase in caspase 3 activity in the P450 2B6-expressing tumors than in the P450-deficient tumors (Figure 1 ). This differential response can be attributed to the activation of CPA locally, within the 9L/2B6 tumor cells, and is consistent with the much stronger antitumor effect seen upon CPA treatment of 9L/2B6 tumors compared to 9L tumors. 17, 28 4-OH-CPA levels in 9L/2B6 and 9L/2B1 tumors Next we investigated whether the P450-dependent increase in CPA-induced apoptosis seen in 9L/2B6 tumors is associated with increased i.t. exposure to 4-OH-CPA, the active metabolite of CPA. Scid mice bearing 9L and 9L/2B6 tumors were treated with CPA by i.p. injection and killed 15 min later. 4-OH-CPA levels were determined in blood, liver and tumor tissue. Blood levels of 4-OH-CPA were significantly higher than those found in the liver in both 9L and 9L/2B6 tumors, indicating rapid clearance of this primary metabolite from its site of production in the liver (Figure 2a) . Surprisingly, i.t. 4-OH-CPA levels were the same in 9L/2B6 tumors as in 9L tumors, indicating that the major fraction of tumorassociated metabolite is formed extratumorally, that is it is derived from hepatic metabolism. A similar pattern was seen 60 min after drug administration (data not shown). 9L tumors expressing P450 2B1, which is a more active CPA 4-hydroxylase than P450 2B6, 29 also showed lower 4-OH-CPA levels in tumor compared to blood and liver (Figure 2b) . A similar result was obtained in 9L/2B1 tumors treated with IFA, an isomer of CPA that is also activated by 4-hydroxylation (Figure 2b) . We conclude that the levels of P450 2B6 and P450 2B1 expressed in these tumors, while very effective at enhancing CPA's antitumor activity, 24 are too low to measurably increase the 4-hydroxy metabolite above the high background level that results from hepatic P450 metabolism.
4-OH-CPA formation in 9L/2B11 tumors
The low K m of P450 2B11 for CPA (B70 mM) translates into superior antitumor activity in vitro and in preclinical P450 gene therapy models. 24 Given this low K m , the therapeutic advantage of P450 2B11 is expected to be manifest at CPA concentrations that are comparatively low (p100 mM), as they are in CPA-treated cancer patients. 30, 31 Indeed, although tumor-associated 4-OH-CPA levels were lower in 9L/2B1 and 9L/2B6 tumors than in liver (Figure 2 ), i.t. 4-OH-CPA concentrations were at least as high, if not higher than in liver in the case of CPAtreated 9L/2B11 tumors (Figure 3a) . Moreover, i.t. 4-OH-CPA concentrations were significantly higher in 9L/2B11 tumors than in 9L tumors over a range of CPA doses (Figure 3b) , consistent with the occurrence of substantial i.t. CPA activation. Intratumoral CPA activation also occurs in the case of the high K m enzymes P450 2B6 and P450 2B1, as evidenced by the enhanced apoptotic response (Figure 1 ) and antitumor effect compared to P450-deficient tumors, 24 but could not be discerned in the context of the high background level of hepatic P450 metabolism. The P450 2B11-dependent increase in i.t. 4-OH-CPA was dose-dependent, without reaching saturation at 140 mg CPA kg À1 BW (Figure 3c ). The inability to saturate the active site of P450 2B11 at this dose, which corresponds to a C max (CPA) of B200 mM, 32 suggests there is restricted uptake of circulating CPA by the tumor cells, reducing the availability of CPA for i.t. metabolism. 
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More detailed pharmacokinetic analyses were carried out to determine how the low K m of P450 2B11 impacts the net exposure of tumor and host tissues to activated CPA. In 9L tumors, which do not metabolize CPA, peak concentrations of 4-OH-CPA were detected in blood and liver as early as 6 min after i.p. CPA injection, while tumor 4-OH-CPA levels reached their peak at the 15 min time point (Figure 4a ). This difference in T max indicates delayed diffusion of 4-OH-CPA from systemic circulation into the tumor. Moreover, at the 6 min time point, the tumor content of 4-OH-CPA was only 40% of that of blood (17.6 vs 45.4 nmol g À1 tissue; Figure 4a ). In contrast, in mice bearing 9L/2B11 tumors, 4-OH-CPA concentrations were higher in tumor than in blood or liver at all times after i.p. CPA administration, except at 6 min, where similar levels of 4-OH-CPA, were found in blood and tumor (Figure 4b ). Pharmacokinetic analysis revealed that, following i.p. CPA treatment, the C max and area under the curve of drug concentration Â time (AUC) of 4-OH-CPA were both significantly higher in 9L/2B11 tumors than in 9L tumors (Table 1) . Collectively, these findings provide strong support for the occurrence of substantial i.t. CPA activation catalyzed by the tumor cell-expressed P450 2B11.
Impact of intratumoral CPA delivery on 4-OH-CPA pharmacokinetics
The impact of localized, i.t. delivery of CPA on the net exposure of 9L/2B11 tumors, and of host tissue, to 4-OH-CPA was investigated. Intratumoral CPA injection increased the C max and AUC values for tumor exposure to 4-OH-CPA by 1.8-and 2.7-fold, respectively, compared to i.p. CPA treatment ( tissue for AUC). Thus, i.t. delivery of CPA increases the availability of CPA for metabolism by the tumor cellexpressed P450 2B11. The enhanced i.t. metabolism of CPA was accompanied by a significant decrease in C max of 4-OH-CPA in both blood and liver, consistent with a shift in CPA metabolism from the liver to the tumor ( Figure 4c vs Figure 4b ; Table 1 ). However, no significant change in the AUC of 4-OH-CPA was observed in either blood or liver when i.t. CPA and i.p. CPA were compared. Next, we investigated whether further increases in i.t. CPA 4-hydroxylation could be achieved using the slow release polymer F127 to increase the residence time of CPA in the tumor, and thereby increase the likelihood that the prodrug will be metabolized by the tumor cellexpressed P450, that is, before it diffuses out from the tumor and into systemic circulation. F127 is soluble at 4 1C but increases in viscosity and forms a gel when the temperature is raised to 37 1C, as occurs following i.t. injection. 33 Intratumoral delivery of CPA using a 23% solution of F127 significantly increased the AUC of tumor-associated 4-OH-CPA when compared to i.t. injection without polymer, and significantly decreased the C max of 4-OH-CPA in both blood and liver ( Figure 4d vs Figure 4c ; Table 1 ). The lower C max in blood suggests that there is reduced exposure of other organs to activated CPA. Both the t 1/2 and the AUC of 4-OH-CPA in liver were increased by i.t. injection of CPA with polymer as compared to i.t. CPA injection without polymer or to i.p. CPA injection (Table 1 ). These findings suggest that the slow release of CPA from its i.t. delivery site decreases Cyclophosphamide was dissolved in 0.2% NaCl (a-c) or in 23% F127/NaCl (d). Data shown are 4-OH-CPA levels (mean7s.e.; n ¼ 3 for blood and liver, n ¼ 6 for tumors). Tissue collection and 4-OH-CPA analysis were as described in Materials and methods. i.t., intratumoral; CPA, cyclophosphamide; i.p., intraperitoneal; BW, body weight. hepatic CPA levels, which in turn leads to metabolism of CPA over an extended period of time.
Impact of intratumoral, slow release CPA delivery on antitumor activity We investigated the impact on antitumor activity of the increased exposure of 9L/2B11 tumors to 4-OH-CPA achieved by using F127 for i.t. CPA delivery. Scid mice bearing 9L/2B11 tumors were treated with CPA using a maximally tolerated dose schedule (2 Â 150 mg CPA kg À1 BW). Cyclophosphamide was administered by i.p. injection or by i.t. injection using F127 as the vehicle. 9L/2B11 tumor growth was halted immediately in both CPA treatment groups (Figure 5a) . However, the mice treated with i.t. CPA/F127 showed significant tumor regression beginning on day 11, whereas tumor regression was not observed in the mice treated with i.p. CPA until day 21 after CPA treatment. Moreover, the maximal tumor regression was significantly higher in the i.t. CPA/ F127 treatment group (87 vs 53% regression; Po0.0005). A second cycle of CPA treatment at day 35 effected substantial tumor growth delay but not tumor regression in either group, perhaps reflecting a preferential killing of P450 2B11-expressing tumor cells in the first treatment cycle and indicating a need for multiple rounds of P450 gene delivery in vivo for effective implementation of this strategy in the clinic. Cyclophosphamide-induced BW loss was more pronounced in the mice receiving CPA via the F127 vehicle, suggesting some intrinsic toxicity of this polymer (Figure 5b ).
Discussion
The efficacy of P450-based gene therapy, like that of other prodrug activation strategies, depends on three key factors: (1) the effectiveness of gene delivery in vivo; (2) the catalytic efficiency of the prodrug activation system; and (3) the biochemical and physicochemical factors that govern the metabolism, pharmacokinetics and cellular responses to the prodrug and its activated metabolites. Recent advances in vector technology have facilitated tumor-selective delivery of prodrug-activation genes and their controlled propagation as regulated by tumorspecific genetic factors and the tumor's physiological state. [34] [35] [36] Significant technical limitations in gene transfer efficiency remain, however, but can in part be compensated for by mutations that increase the catalytic activity or efficiency of the prodrug activation gene. [37] [38] [39] In the case of cytochrome P450, the low catalytic efficiency of the high K m CPA 4-hydroxylase enzymes P450 2B1 and P450 2B6 toward the anticancer prodrug substrate CPA (K m B500-1500 mM) can be greatly improved by the use of P450 2B11, a low K m CPA 4-hydroxylase (K m B70 mM). 24 Presently, we used scid mice bearing 9L gliosarcomas transduced with retrovirus encoding either high K m or low K m CPA-activating P450 enzymes as a model system to characterize the metabolic and pharmacokinetic factors that underlie this improved activity and to investigate the impact of i.t. CPA delivery using a slow release polymer.
Tissue concentrations of 4-OH-CPA, the primary activated metabolite of CPA, were lower in tumor than in blood and liver following CPA treatment of mice bearing 9L/2B6 and 9L/2B1 tumors. Moreover, i.t. 4-OH-CPA levels in 9L/2B6 and 9L/2B1 tumors were indistinguishable from those in P450-deficient 9L tumors. A similar observation was made in the case of human glioma xenografts infected with Herpes virus encoding P450 2B1. 40 Thus, in mice with tumors expressing P450 2B6 or P450 2B1, the vast majority of tumor-associated 4-OH-CPA is still derived from the liver, which is much larger in size and has a higher content of cytochrome P450 than the P450-expressing tumors. Nevertheless, 9L/ 2B6 and 9L/2B1 tumors both display enhanced CPA chemosensitivity 13, 28 and enhanced apoptotic responses compared to control 9L tumors, as was shown for Figure 1 ). This suggests that while liver-derived 4-OH-CPA may readily enter blood vessels associated with 9L tumors, it has only limited access to the relevant tumor cell compartments. As a consequence, liver-derived 4-OH-CPA is apparently much less effective at inducing tumor cell apoptosis and an overall antitumor response when compared to a much lower level of 4-OH-CPA formed directly within tumor cells via i.t. P450 metabolism. Of note, 4-OH-CPA undergoes chemical decomposition to release phosphoramide mustard, a DNA crosslinking agent and the ultimate therapeutic metabolite, which unlike 4-OH-CPA, has restricted cell membrane permeability. 41 Accordingly, any 4-OH-CPA molecules that decompose to phosphoramide mustard within tumorassociated blood vessels, or within the initial layers of tumor cells adjacent to the tumor vasculature, are unlikely to induce widespread tumor cell cytotoxic responses. Circulating 4-OH-CPA itself also appears to have restricted access to 9L tumors, as indicated by the 4-OH-CPA levels being consistently lower in the 9L tumors than in blood or liver, despite the fact that 9L tumors are well vascularized. 42 In contrast to 9L/2B6 and 9L/2B1 tumors, whose catalysis of 4-OH-CPA formation was undetectable in the context of the high background of liver-derived 4-OH-CPA, i.t. formation of 4-OH-CPA by 9L/2B11 tumors was readily evident following systemic CPA administration and was associated with 4-OH-CPA levels significantly higher than in blood and liver. The high level of i.t. CPA activation thus achieved in 9L/2B11 tumors is likely to be key to the substantially improved CPA antitumor response displayed in gene therapy models using P450 2B11 as compared to P450 2B6 or P450 2B1. 24 Together, these findings provide proof-of-principle for the use of low K m prodrug-activation enzymes, such as P450 2B11 and improved variants, 43 to augment i.t. prodrug activation at pharmacologically relevant prodrug dosages. These findings will need to be verified using viral or other gene therapy vectors to deliver P450 genes to solid tumors in vivo, where P450 protein expression is likely to be much realized in a much smaller fraction of tumor cells than the up to 50% tumor cell coverage seen here.
Physiological conditions associated with solid tumors often lead to poor drug uptake, 44, 45 which in the case of prodrug activation gene therapy may translate into inefficient prodrug activation. Presently, 4-OH-CPA production by P450 2B11-expressing 9L tumors was not saturated at a prodrug dose corresponding to a C max (CPA) of B200 mM, that is B3 times the observed K m of P450 2B11, suggesting inefficient penetration of CPA, despite the good vascularity of 9L tumors. To circumvent this problem, CPA was administered by direct i.t. injection, which significantly improved i.t. 4-OH-CPA pharmacokinetics, as evidenced by a 1.8-fold increase in C max and a 2.7-fold increase in AUC compared to systemic CPA treatment. Further improvements were obtained using the slow release polymer poloxamer 407 (F127) as vehicle for CPA delivery. This biocompatible polymer dissolves in aqueous solution at 4 1C, but rapidly forms a gel upon shifting the temperature to 37 1C and can be used to effect slow release of lipophilic drugs and other small molecules as well as large particles such as viruses. 23, 33, 46 Overall exposure of the tumor mass to 4-OH-CPA was increased 3.9-fold by i.t. CPA delivery via the slow release polymer, as indicated by AUC, and antitumor activity was correspondingly enhanced, as indicated by early onset and more extensive tumor regression. The effective increase in tumor cell exposure to 4-OH-CPA is likely to be even greater than the measured 3.9-fold increase in AUC, given that a substantial fraction of the AUC (4-OH-CPA) under conditions of i.p. CPA treatment is liver-derived 4-OH-CPA, which as discussed above, has poor access to the relevant tumor cell compartment. Peak host tissue 4-OH-CPA levels were also reduced with i.t. CPA delivery, both with and without the slow release polymer, and this may translate into a reduction of toxicity to sensitive host tissues. Localized chemotherapy may thus be used to shift the partitioning of P450 prodrug from the liver to the tumor. This general strategy may be implemented in a variety of ways, including using other slow release polymers that may be better optimized for small hydrophilic drugs such as CPA 40 or may be more suitable for clinical studies, or by localized instillation of prodrug to the tumor vasculature, as exemplified by preclinical and clinical studies of P450 prodrug gene therapy in pancreatic cancer. 21, 47 Abbreviations AUC, area under the curve of drug concentration Â time; BW, body weight; C max , maximum concentration; CPA, cyclophosphamide; DMEM, Delbecco's modified Eagle's medium; F127, Pluronic F127 or poloxamer 407 block copolymer; FBS, fetal bovine serum; IFA, ifosfamide.
